Gibson James E, Taylor David A
Department of Pharmacology and Toxicology, The Brody School of Medicine at East Carolina University, Greenville, NC 27834, USA.
J Pharmacol Exp Ther. 2005 Sep;314(3):939-44. doi: 10.1124/jpet.105.085712. Epub 2005 Apr 15.
The safety and effectiveness of over-the-counter (OTC) drugs are assessed through the Food and Drug Administration's (FDA's) OTC drug review. Prescription drugs are approved through the rigorous new drug application (NDA) process. In contrast, dietary supplements are regulated as foods, and the FDA must determine that a dietary supplement ingredient poses a "significant or unreasonable risk of illness or injury" instead of requiring the manufacturer to provide safety data. According to the FDA, there are more than 29,000 different dietary supplements available to consumers today. This momentum has its roots in consumer interest in health and self-care and suggests that Americans are searching for alternatives to conventional foods for physical and mental well being. The Committee on the Framework for Evaluating the Safety of Dietary Supplements was formed under the auspices of the Food and Nutrition Board that produced a report entitled Dietary Supplements: A Framework for Evaluating Safety. Categories of specific information identified for use are 1) human data, 2) animal studies, 3) in vitro experiments, and 4) information on related substances. Several factors were identified to guide the FDA in applying the framework. Two of these factors are expressed as follows: 1) "the appropriate scientific standard to be used to overturn this basic assumption of safety is to demonstrate significant or unreasonable risk, not prove that an ingredient is unsafe"; and 2) "approaches taken by diverse organizations and governmental bodies, both within and outside the United States, which evaluate the safety and at times efficacy of dietary supplement ingredients, vary in their relevance to the protection of the American public from risks associated with consumption of dietary supplement ingredients".
非处方药(OTC)的安全性和有效性是通过美国食品药品监督管理局(FDA)的非处方药审查来评估的。处方药则通过严格的新药申请(NDA)程序获得批准。相比之下,膳食补充剂作为食品受到监管,FDA必须确定一种膳食补充剂成分是否构成“重大或不合理的疾病或伤害风险”,而不是要求制造商提供安全数据。据FDA称,如今消费者可以获得超过29000种不同的膳食补充剂。这种趋势源于消费者对健康和自我保健的兴趣,表明美国人正在寻找传统食品之外的身心保健替代品。膳食补充剂安全性评估框架委员会是在食品与营养委员会的主持下成立的,该委员会发表了一份题为《膳食补充剂:安全性评估框架》的报告。确定使用的具体信息类别包括:1)人体数据;2)动物研究;3)体外实验;4)相关物质信息。确定了几个因素来指导FDA应用该框架。其中两个因素如下:1)“推翻这种基本安全假设应采用的适当科学标准是证明存在重大或不合理风险,而不是证明一种成分不安全”;2)“美国国内外不同组织和政府机构评估膳食补充剂成分安全性以及有时评估其有效性时所采用的方法,在保护美国公众免受与食用膳食补充剂成分相关风险方面的相关性各不相同”。